Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | CD4 | P01730 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25221649 | 0.96 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1HSP90B1BDKRB1MCHR1 | |
| SCHEMBL30301765 | 0.89 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1HSP90B1BDKRB1KDM4E | |
| SCHEMBL30301742 | 0.88 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1HSP90B1KDM4EALDH1A1 | |
| SCHEMBL30462427 | 0.88 | ALDH1A1 (0.33) | BDKRB1MCHR1KDM4EALDH1A1F2 | |
| SCHEMBL25234807 | 0.88 | ALDH1A1 (0.33) | BDKRB1MCHR1KDM4EALDH1A1F2 | |
| SCHEMBL25214972 | 0.86 | QRFPR (0.42) | ALDH1A1CD4ACACB | |
| SCHEMBL25228227 | 0.83 | BDKRB1 (0.35) | HSP90AA1HSP90AB1BDKRB1 | |
| SCHEMBL29263207 | 0.81 | LMNA (0.40) | HSP90AA1HSP90AB1KDM4EALDH1A1STAT3 | |
| SCHEMBL30301590 | 0.81 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1HSP90B1MCHR1ALDH1A1 | |
| SCHEMBL25212540 | 0.80 | F2 (0.36) | CD4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| EP-4157463-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | HSP90AA1 2502/4885HSP90AB1 1847/4885HSP90B1 3336/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | HSP90AA1 1915/4885HSP90AB1 1434/4885HSP90B1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.